Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (881)	12/18/2003 11:02:56 AM
From: keokalani'nui	Respond to of 1005

I've been meaning to do the same and promise I will someday.

To: tuck who wrote (881)	12/22/2003 3:19:06 PM
From: scaram(o)uche	Respond to of 1005

Genitope.... it's even more complex than just the "personalized" angle. We've discussed this before, somewhere. Sigh, sure wish SI's search function was worth crap. 1. unlike most "cancer antigens", the idiotype of NHL is real. the target for this vaccine WILL allow for effective and specific anti-cancer responses. 2. however, the antigen is unfortunately defined by a genetic region which is known for it's astronomically high rate of somatic mutation. So, you win some, you lose some. Idec has tried the concept, with a little less spit and shine. Remissions were not durable. I mentioned that (and the LSBC project) to Genitope's CEO a two or three years ago at H&Q. He said that, if the patients do relapse with an antigen-negative cancer, their system is fast enough to just treat the patient's then-problematic idiotype. Easy to say. I haven't looked at the S-1. Please forgive any ignorance that may derive from not having looked at them in 2-3 years. This may all be old news.